February 2, 2024 News by Patricia Inacio, PhD Tysabri biosimilar Tyruko now available in Germany for RRMS TyrukoĀ (natalizumab), the first biosimilar ofĀ Tysabri,Ā is now available in Germany forĀ adults with highly active relapsing-remitting multiple sclerosis (RRMS). As a biosimilar, Tyruko has the same safety and efficacy profile, mechanism of action, and pharmacological properties as Tysabri. Biosimilars are typically sold at lower prices than their reference medication,…
August 10, 2023 News by Lindsey Shapiro, PhD Physical activity may reduce fatigue in people with RRMS: Trial More daily physical activity, better physical condition, and lower disability were all associated with less fatigue for people with relapsing-remitting multiple sclerosis (RRMS), according to a clinical trial in Finland. āThe findings are interesting and support previous studies very well,” Marko Luostarinen, a doctoral researcher at the University of…
September 2, 2022 News by Marta Figueiredo, PhD Delayed Ocrevus Infusion May Increase MRI-based RRMS Risk An extended interval between maintenance doses of OcrevusĀ (ocrelizumab) may increase the risk of MRI-based disease activity in people with relapsing-remitting multiple sclerosisĀ (RRMS), according to a real-world, multicenter study in Italy. In fact, an extended interval dosing (by one month or longer) was associated with a fivefold higher risk…
July 26, 2021 News by Forest Ray PhD At-home Tysabri Infusions Appear as Safe, Effective as Those at Clinics Tysabri (natalizumab) infusions given in the home to people with relapsing-remitting multiple sclerosis (RRMS) save money and are more convenient, while apparently as safe and effective as those given in clinical settings, a pilot study comparing the two delivery methods reported. Nonetheless, its researchers recommended larger trials be…
July 29, 2019 News by Patricia Inacio, PhD Early Gilenya Treatment Lessens Disability Progression and Disease Activity in Young RRMS Patients, Study Shows Early and continuous treatment with Gilenya (fingolimod) in youngĀ people ā those ages 30 years or younger ā with relapsing-remitting multiple sclerosis (RRMS) decreases the risk of disability progression, and lowers annual relapse rates and brain lesions, new analysis from the FREEDOMS and FREEDOMS II trials show. The…
July 2, 2019 News by Ana Pena PhD Neurologists Prefer Mayzent for SPMS and RRMS, But Mavenclad Could Be ‘Ideal’ First Switch, Report Suggests While neurologists favor Novartis‘ Mayzent (siponimod) for people with active secondary progressive multiple sclerosis (SPMS) and transitioning relapsing-remitting MS (RRMS), EMD Serono‘s Mavenclad (cladribine) could serve as a first option for patients with RRMS who failed initial therapy, Spherix Global Insights says in its…
October 18, 2018 Columns by Jennifer (Jenn) Powell SPMS and the Continuum of Acceptance Some days are hard, while others are still harder. Then there are days that bring you to your knees. I am kneeling. Pain ricochets through my body like a pinball machine on tilt. Flashing lights dance as if to announce the imminent. “Danger, Will Robinson!” I hit…